DanceTherParkinsonV1, Ncbi, Curation, bibRecord, 000002

Protracted venous infusion 5-fluorouracil in combination with subcutaneous interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer: a phase II study

Identifieur interne : 000002 ( Ncbi/Curation ); précédent : 000001; suivant : 000003

Protracted venous infusion 5-fluorouracil in combination with subcutaneous interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer: a phase II study

Auteurs : M J Allen [Royaume-Uni] ; M. Vaughan [Royaume-Uni] ; A. Webb [Royaume-Uni] ; S. Johnston [Royaume-Uni] ; P. Savage [Royaume-Uni] ; T. Eisen [Royaume-Uni] ; S. Bate [Royaume-Uni] ; J. Moore [Royaume-Uni] ; R. Ahern [Royaume-Uni] ; M E Gore [Royaume-Uni]

Source :

British Journal of Cancer [ 0007-0920 ] ; 2000.

RBID : PMC:2363554

Abstract

Our purpose was to assess the activity of alpha-interferon (IFN-α), interleukin-2 (IL-2) and 5 fluorouracil (5FU) administered by protracted venous infusion (PVI) as opposed to bolus injection. 55 patients with advanced renal cell cancer were treated as follows: IL-2 and IFN-α according to the schedule originally described by Atzpodien, with PVI 5FU 200 mg m^–2 day^–1 during weeks 5–9. 42 patients (76%) were of moderate or poor prognosis as defined by previous studies. The response rate by intention to treat was 31% (17 of 55, three complete response, 14 partial response; 95% CI = 19–45%) and in evaluable patients (completed one cycle, n = 42), it was 40% (95% CI = 26–57%). In addition, 24% (13 of 55) patients achieved disease stabilization. The overall median survival was 11 months with a 1-year survival of 45%. The median survival for evaluable patients was 18 months with 1- and 2-year survivals of 60% and 40% respectively. The median survival of responding patients was 31 months and the three patients achieving complete response remain progression-free at 14+, 18+ and 23+ months. Evaluable patients with poor prognostic features achieved a response rate of 54% and median survival of 18 months. Toxicity was significant yet manageable with 12 patients unable to complete one cycle due to side-effects and 36% experiencing grade 3–4 toxicities. The three on-treatment deaths were considered unlikely to be due to toxicity. The schedule of IFN-α, IL-2 and PVI 5FU has significant activity in advanced renal cell cancer with manageable toxicity. It is of particular interest that this regimen appears to have high activity in fit patients with poor prognostic features. © 2000 Cancer Research Campaign

Url:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363554

DOI: 10.1054/bjoc.2000.1418
PubMed: 10993642
PubMed Central: 2363554

Links toward previous steps (curation, corpus...)

to stream Pmc, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000001
to stream Pmc, to step Curation: Pour aller vers cette notice dans l'étape Curation :000001
to stream Pmc, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000187
to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :000002

Links to Exploration step

PMC:2363554

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Protracted venous infusion 5-fluorouracil in combination with subcutaneous interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer: a phase II study</title>
<author><name sortKey="Allen, M J" sort="Allen, M J" uniqKey="Allen M" first="M J" last="Allen">M J Allen</name>
<affiliation wicri:level="3"><nlm:aff id="aff1">Royal Marsden Hospital, London, UK</nlm:aff>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Royal Marsden Hospital, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Vaughan, M" sort="Vaughan, M" uniqKey="Vaughan M" first="M" last="Vaughan">M. Vaughan</name>
<affiliation wicri:level="3"><nlm:aff id="aff1">Royal Marsden Hospital, London, UK</nlm:aff>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Royal Marsden Hospital, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Webb, A" sort="Webb, A" uniqKey="Webb A" first="A" last="Webb">A. Webb</name>
<affiliation wicri:level="3"><nlm:aff id="aff1">Royal Marsden Hospital, London, UK</nlm:aff>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Royal Marsden Hospital, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Johnston, S" sort="Johnston, S" uniqKey="Johnston S" first="S" last="Johnston">S. Johnston</name>
<affiliation wicri:level="3"><nlm:aff id="aff1">Royal Marsden Hospital, London, UK</nlm:aff>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Royal Marsden Hospital, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Savage, P" sort="Savage, P" uniqKey="Savage P" first="P" last="Savage">P. Savage</name>
<affiliation wicri:level="3"><nlm:aff id="aff1">Royal Marsden Hospital, London, UK</nlm:aff>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Royal Marsden Hospital, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Eisen, T" sort="Eisen, T" uniqKey="Eisen T" first="T" last="Eisen">T. Eisen</name>
<affiliation wicri:level="3"><nlm:aff id="aff1">Royal Marsden Hospital, London, UK</nlm:aff>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Royal Marsden Hospital, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bate, S" sort="Bate, S" uniqKey="Bate S" first="S" last="Bate">S. Bate</name>
<affiliation wicri:level="3"><nlm:aff id="aff1">Royal Marsden Hospital, London, UK</nlm:aff>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Royal Marsden Hospital, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Moore, J" sort="Moore, J" uniqKey="Moore J" first="J" last="Moore">J. Moore</name>
<affiliation wicri:level="3"><nlm:aff id="aff1">Royal Marsden Hospital, London, UK</nlm:aff>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Royal Marsden Hospital, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ahern, R" sort="Ahern, R" uniqKey="Ahern R" first="R" last="Ahern">R. Ahern</name>
<affiliation wicri:level="3"><nlm:aff id="aff1">Royal Marsden Hospital, London, UK</nlm:aff>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Royal Marsden Hospital, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Gore, M E" sort="Gore, M E" uniqKey="Gore M" first="M E" last="Gore">M E Gore</name>
<affiliation wicri:level="3"><nlm:aff id="aff1">Royal Marsden Hospital, London, UK</nlm:aff>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Royal Marsden Hospital, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">10993642</idno>
<idno type="pmc">2363554</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363554</idno>
<idno type="RBID">PMC:2363554</idno>
<idno type="doi">10.1054/bjoc.2000.1418</idno>
<date when="2000">2000</date>
<idno type="wicri:Area/Pmc/Corpus">000001</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000001</idno>
<idno type="wicri:Area/Pmc/Curation">000001</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000001</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000187</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000187</idno>
<idno type="wicri:Area/Ncbi/Merge">000002</idno>
<idno type="wicri:Area/Ncbi/Curation">000002</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Protracted venous infusion 5-fluorouracil in combination with subcutaneous interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer: a phase II study</title>
<author><name sortKey="Allen, M J" sort="Allen, M J" uniqKey="Allen M" first="M J" last="Allen">M J Allen</name>
<affiliation wicri:level="3"><nlm:aff id="aff1">Royal Marsden Hospital, London, UK</nlm:aff>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Royal Marsden Hospital, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Vaughan, M" sort="Vaughan, M" uniqKey="Vaughan M" first="M" last="Vaughan">M. Vaughan</name>
<affiliation wicri:level="3"><nlm:aff id="aff1">Royal Marsden Hospital, London, UK</nlm:aff>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Royal Marsden Hospital, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Webb, A" sort="Webb, A" uniqKey="Webb A" first="A" last="Webb">A. Webb</name>
<affiliation wicri:level="3"><nlm:aff id="aff1">Royal Marsden Hospital, London, UK</nlm:aff>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Royal Marsden Hospital, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Johnston, S" sort="Johnston, S" uniqKey="Johnston S" first="S" last="Johnston">S. Johnston</name>
<affiliation wicri:level="3"><nlm:aff id="aff1">Royal Marsden Hospital, London, UK</nlm:aff>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Royal Marsden Hospital, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Savage, P" sort="Savage, P" uniqKey="Savage P" first="P" last="Savage">P. Savage</name>
<affiliation wicri:level="3"><nlm:aff id="aff1">Royal Marsden Hospital, London, UK</nlm:aff>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Royal Marsden Hospital, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Eisen, T" sort="Eisen, T" uniqKey="Eisen T" first="T" last="Eisen">T. Eisen</name>
<affiliation wicri:level="3"><nlm:aff id="aff1">Royal Marsden Hospital, London, UK</nlm:aff>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Royal Marsden Hospital, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bate, S" sort="Bate, S" uniqKey="Bate S" first="S" last="Bate">S. Bate</name>
<affiliation wicri:level="3"><nlm:aff id="aff1">Royal Marsden Hospital, London, UK</nlm:aff>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Royal Marsden Hospital, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Moore, J" sort="Moore, J" uniqKey="Moore J" first="J" last="Moore">J. Moore</name>
<affiliation wicri:level="3"><nlm:aff id="aff1">Royal Marsden Hospital, London, UK</nlm:aff>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Royal Marsden Hospital, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ahern, R" sort="Ahern, R" uniqKey="Ahern R" first="R" last="Ahern">R. Ahern</name>
<affiliation wicri:level="3"><nlm:aff id="aff1">Royal Marsden Hospital, London, UK</nlm:aff>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Royal Marsden Hospital, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Gore, M E" sort="Gore, M E" uniqKey="Gore M" first="M E" last="Gore">M E Gore</name>
<affiliation wicri:level="3"><nlm:aff id="aff1">Royal Marsden Hospital, London, UK</nlm:aff>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Royal Marsden Hospital, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">British Journal of Cancer</title>
<idno type="ISSN">0007-0920</idno>
<idno type="eISSN">1532-1827</idno>
<imprint><date when="2000">2000</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p>Our purpose was to assess the activity of alpha-interferon (IFN-α), interleukin-2 (IL-2) and 5 fluorouracil (5FU) administered by protracted venous infusion (PVI) as opposed to bolus injection. 55 patients with advanced renal cell cancer were treated as follows: IL-2 and IFN-α according to the schedule originally described by Atzpodien, with PVI 5FU 200 mg m<sup>–2</sup>
 day<sup>–1</sup>
 during weeks 5–9. 42 patients (76%) were of moderate or poor prognosis as defined by previous studies. The response rate by intention to treat was 31% (17 of 55, three complete response, 14 partial response; 95% CI = 19–45%) and in evaluable patients (completed one cycle, <italic>n</italic>
 = 42), it was 40% (95% CI = 26–57%). In addition, 24% (13 of 55) patients achieved disease stabilization. The overall median survival was 11 months with a 1-year survival of 45%. The median survival for evaluable patients was 18 months with 1- and 2-year survivals of 60% and 40% respectively. The median survival of responding patients was 31 months and the three patients achieving complete response remain progression-free at 14+, 18+ and 23+ months. Evaluable patients with poor prognostic features achieved a response rate of 54% and median survival of 18 months. Toxicity was significant yet manageable with 12 patients unable to complete one cycle due to side-effects and 36% experiencing grade 3–4 toxicities. The three on-treatment deaths were considered unlikely to be due to toxicity. The schedule of IFN-α, IL-2 and PVI 5FU has significant activity in advanced renal cell cancer with manageable toxicity. It is of particular interest that this regimen appears to have high activity in fit patients with poor prognostic features. © 2000 Cancer Research Campaign</p>
</div>
</front>
</TEI>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Psychologie/explor/DanceTherParkinsonV1/Data/Ncbi/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000002 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 000002 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Psychologie
   |area=    DanceTherParkinsonV1
   |flux=    Ncbi
   |étape=   Curation
   |type=    RBID
   |clé=     PMC:2363554
   |texte=   Protracted venous infusion 5-fluorouracil in combination with subcutaneous interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer: a phase II study
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i   -Sk "pubmed:10993642" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a DanceTherParkinsonV1

This area was generated with Dilib version V0.6.35.
Data generation: Sun Aug 9 17:42:30 2020. Site generation: Wed Sep 30 11:15:33 2020

	Danse-thérapie et Parkinson
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Danse-thérapie et Parkinson

Protracted venous infusion 5-fluorouracil in combination with subcutaneous interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer: a phase II study

Protracted venous infusion 5-fluorouracil in combination with subcutaneous interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer: a phase II study

Source :

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki